Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Adipocyte-derived stem cell-based gene therapy upon adipogenic differentiation on microcarriers attenuates type 1 diabetes in mice

Fig. 6

AD-AP2-INS cells seeded on microcarriers alleviate hyperglycemia in diabetic mouse models. ad Empty cytopore 1 microcarrier (MC), AD-AP2-INS-EGFP cells (Cell), or AD-AP2-INS-EGFP cells seeded on MCs (Cell+MC) injected into the inguinal fat pad in STZ-induced diabetic mice (n = 5). a Blood glucose was monitored at indicated time points. C-peptide (b) and insulin (c) measured at 28 days after treatment. Data were presented as mean ± SD. *p < 0.05 and **p < 0.01, vs untreated control group (-), were considered significant. d Detection of transplanted cells on the microcarrier. Immunofluorescence against EGFP on the cross sections of a tissue-like structure formed in the Cell+MC group. Scale bar, 50 μm. e, f Empty cytopore 1 microcarrier (MC, n = 3) and AD-AP2-INS-EGFP cells seeded on MCs (Cell+MC and Cell+MC, n = 4) were injected into the inguinal fat pad in STZ-induced diabetic mice. In the group of MC+Cell-R, the MC+Cell was removed on day 14 as indicated by the arrows. Blood glucose (e) and insulin (f) were monitored at indicated time points. Data were presented as mean ± SD. #p < 0.05 vs the MC group; *p < 0.05 as labeled was considered significant

Back to article page